Scholarlink

Purpose <p>This study aims to identify recurring Quality Management Systems (QMS) deficiency patterns by analyzing recent U.S. Food and Drug Administration (FDA) inspection and citation data from 2023 to 2025. The primary research questions focus on the most frequent QMS failure categories, their geographic and temporal trends, and strategies for implementing risk-based quality improvements.</p> Methods <p>A quantitative secondary data analysis was conducted using FDA inspection outcomes and citation data classified into No Action Indicated (NAI), Voluntary Action Indicated (VAI), and Official Action Indicated (OAI). Citations were mapped to 19 standardized QMS failure categories aligned with 21 CFR Part 211 subparts. A Risk Priority Index (RPI) was developed to prioritize failure modes based on severity-weighted inspection frequencies. Descriptive and comparative analyses were performed by region and year.</p> Results <p>The study analyzed 2,618 FDA pharmaceutical inspections worldwide, revealing 3,564 citations primarily concentrated in procedure-related failures, quality control (QC) deficiencies, and corrective and preventive actions (CAPA) issues. Together with seven additional high-impact categories, these accounted for approximately 82% of the total RPI. Geographic variation in citation rates was observed, with higher citation densities in the U.S., India, and parts of Asia, accompanied by variation in observed citation patterns. Temporal trends indicated a rising proportion of inspections resulting in posted citations.</p> Conclusion <p>Recurring QMS citation patterns were most frequently associated with procedural controls, QC, and CAPA, suggesting area for targeted risk-based remediation. Implementation of harmonized, data-driven QMS frameworks supported by digital tools and leadership accountability may help improve regulatory preparedness and quality system performance. These findings offer structured analytical insights that may inform quality improvement planning and regulatory awareness.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Data-driven Insights from FDA Inspections for Pharmaceutical Quality Management System Improvement

  • 期刊论文

  • 发表日期：

    2026年3月26日

查看全文
  • Lantider K. Bekele,
  • Christopher J. Kluse,
  • M. Affan Badar

摘要

Purpose

This study aims to identify recurring Quality Management Systems (QMS) deficiency patterns by analyzing recent U.S. Food and Drug Administration (FDA) inspection and citation data from 2023 to 2025. The primary research questions focus on the most frequent QMS failure categories, their geographic and temporal trends, and strategies for implementing risk-based quality improvements.

Methods

A quantitative secondary data analysis was conducted using FDA inspection outcomes and citation data classified into No Action Indicated (NAI), Voluntary Action Indicated (VAI), and Official Action Indicated (OAI). Citations were mapped to 19 standardized QMS failure categories aligned with 21 CFR Part 211 subparts. A Risk Priority Index (RPI) was developed to prioritize failure modes based on severity-weighted inspection frequencies. Descriptive and comparative analyses were performed by region and year.

Results

The study analyzed 2,618 FDA pharmaceutical inspections worldwide, revealing 3,564 citations primarily concentrated in procedure-related failures, quality control (QC) deficiencies, and corrective and preventive actions (CAPA) issues. Together with seven additional high-impact categories, these accounted for approximately 82% of the total RPI. Geographic variation in citation rates was observed, with higher citation densities in the U.S., India, and parts of Asia, accompanied by variation in observed citation patterns. Temporal trends indicated a rising proportion of inspections resulting in posted citations.

Conclusion

Recurring QMS citation patterns were most frequently associated with procedural controls, QC, and CAPA, suggesting area for targeted risk-based remediation. Implementation of harmonized, data-driven QMS frameworks supported by digital tools and leadership accountability may help improve regulatory preparedness and quality system performance. These findings offer structured analytical insights that may inform quality improvement planning and regulatory awareness.